IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

FAVALLI, ENNIO GIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.888
NA - Nord America 6.187
EU - Europa 5.628
SA - Sud America 933
AF - Africa 218
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 11
Totale 19.902
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.852
SG - Singapore 2.074
CN - Cina 2.064
IT - Italia 1.558
DE - Germania 739
GB - Regno Unito 724
BR - Brasile 697
HK - Hong Kong 639
VN - Vietnam 627
RU - Federazione Russa 568
FR - Francia 391
BD - Bangladesh 342
SE - Svezia 335
NL - Olanda 274
IN - India 272
CA - Canada 211
FI - Finlandia 209
IE - Irlanda 205
ID - Indonesia 150
JP - Giappone 148
ES - Italia 142
TR - Turchia 142
AR - Argentina 86
CI - Costa d'Avorio 83
KR - Corea 71
MX - Messico 64
UA - Ucraina 57
PL - Polonia 54
GR - Grecia 52
IQ - Iraq 51
AT - Austria 49
DK - Danimarca 47
CO - Colombia 43
TW - Taiwan 38
CH - Svizzera 35
AU - Australia 33
RO - Romania 33
BE - Belgio 30
PK - Pakistan 30
ZA - Sudafrica 29
IL - Israele 28
PE - Perù 27
PH - Filippine 27
CZ - Repubblica Ceca 23
MY - Malesia 23
UZ - Uzbekistan 23
EC - Ecuador 22
EG - Egitto 21
PT - Portogallo 21
SA - Arabia Saudita 21
CL - Cile 20
MA - Marocco 20
IR - Iran 19
EU - Europa 18
VE - Venezuela 18
TH - Thailandia 17
AE - Emirati Arabi Uniti 13
DZ - Algeria 13
TN - Tunisia 13
LT - Lituania 12
NO - Norvegia 11
HU - Ungheria 10
JM - Giamaica 10
JO - Giordania 10
KE - Kenya 9
PA - Panama 9
BA - Bosnia-Erzegovina 8
BG - Bulgaria 8
HR - Croazia 8
PY - Paraguay 8
UY - Uruguay 8
CR - Costa Rica 6
DO - Repubblica Dominicana 6
ET - Etiopia 6
TT - Trinidad e Tobago 6
AZ - Azerbaigian 5
HN - Honduras 5
KW - Kuwait 5
KZ - Kazakistan 5
LB - Libano 5
LU - Lussemburgo 5
MD - Moldavia 5
AM - Armenia 4
AP - ???statistics.table.value.countryCode.AP??? 4
BO - Bolivia 4
CY - Cipro 4
KG - Kirghizistan 4
LA - Repubblica Popolare Democratica del Laos 4
NZ - Nuova Zelanda 4
PR - Porto Rico 4
SC - Seychelles 4
SI - Slovenia 4
SV - El Salvador 4
AL - Albania 3
NI - Nicaragua 3
NP - Nepal 3
OM - Oman 3
PS - Palestinian Territory 3
SN - Senegal 3
SY - Repubblica araba siriana 3
Totale 19.870
Salva come PNG Salva come JPEG
Città #
Singapore 1.103
Ashburn 811
Hong Kong 520
Southend 430
San Jose 421
Milan 410
Chandler 388
Dallas 303
Beijing 278
Hanover 248
Los Angeles 218
Santa Clara 218
Council Bluffs 209
Ho Chi Minh City 209
Dublin 199
New York 190
Princeton 179
Frankfurt am Main 176
Guangzhou 167
Fairfield 165
Hefei 150
Hanoi 149
Helsinki 148
Wilmington 134
Lauterbourg 133
Moscow 132
Redwood City 123
Bengaluru 114
Jakarta 108
Rome 102
Seattle 93
Houston 89
Toronto 89
Abidjan 83
Cambridge 82
Woodbridge 80
Shanghai 79
Buffalo 76
São Paulo 76
Tokyo 67
Munich 66
Central District 55
Boardman 51
Des Moines 51
Ann Arbor 50
Cangzhou 50
London 50
Madrid 48
Istanbul 44
Nanjing 43
Chicago 40
Montreal 37
Shenzhen 36
Haiphong 34
Jacksonville 34
Changsha 33
Bologna 32
Da Nang 32
Dearborn 32
Phoenix 32
San Diego 32
Turin 31
Jinan 29
Seoul 29
Shenyang 29
Columbus 27
Grafing 26
Amsterdam 25
Atlanta 24
Berlin 24
Medford 24
Tianjin 24
Nuremberg 23
San Francisco 23
Washington 23
Naples 22
Sunnyvale 22
Vienna 22
Athens 21
Florence 21
The Dalles 21
Turku 21
Bogotá 20
Edinburgh 20
Lappeenranta 19
Redmond 19
Rio de Janeiro 19
Serra 19
Belo Horizonte 18
Fuzhou 18
Rho 18
Taipei 18
Wuhan 18
Hangzhou 17
Orem 17
Porto Alegre 17
Tashkent 17
Zhengzhou 17
Zurich 17
Brooklyn 16
Totale 10.666
Salva come PNG Salva come JPEG
Nome #
Biomarkers in psoriatic arthritis : a systematic literature review 1.437
Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis : A multi-center retrospective analysis 469
The Expanded Risk Score in Rheumatoid Arthritis (ERS-RA): performance of a disease-specific calculator in comparison with the traditional prediction scores in the assessment of the 10-year risk of cardiovascular disease in patients with rheumatoid arthrit 428
Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus 394
Are patients with systemic lupus erythematosus at increased risk for COVID-19? 364
Activation of inflammation, coagulation and fibrinolysis in patients with Rheumatoid Arthritis : inhibition by Tumor Necrosis Factor alpha blockade 363
Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis : effects of tumor necrosis factor-alpha blockade 328
Real-world 6 and 12-month drug retention, remission and response rates of secukinumab in 2,017 psoriatic arthritis patients in 13 European countries 314
Prédicteurs de la réponse aux traitements anti-TNF chez les patients ayant une polyarthrite rhumatoïde avec des scores DAS28 modérés ou élevés 312
COVID-19 infection and rheumatoid arthritis: Faraway, so close! 309
Baricitinib for COVID-19: a suitable treatment? 264
Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis 259
Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic 247
Haemostatic and inflammatory biomarkers in patients with rheumatoid arthritis : effect of tumor necrosis factor alpha blockade 231
Effetto della terapia con infliximab sui marcatori di infiammazione, coagulazione e fibrinolisi nell’artrite reumatoide 229
Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients 224
Comments on “Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials : a multicenter retrospective study” 215
Potential short-term air pollution effects on rheumatoid arthritis activity in metropolitan areas in the North of Italy : A cross-sectional study 215
Haemostatic and inflammatory biomarkers in patients with active Rheumatoid Arthritis : effects of Tumor Necrosis Factor alpha blockade 210
Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors 210
The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events 203
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations 201
Effect of tumor necrosis factor alpha blockade on inflammatory and haemostatic biomarkers in patients with rheumatoid arthritis 196
Reduction of haemostatic and inflammatory biomarkers by tumor necrosis factor-alpha bockade in patients with rheumatoid arthritis 188
Role of antimalarials in COVID-19 : observational data from a cohort of rheumatic patients 183
Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA 182
COVID-19 and what pediatric rheumatologists should know: A review from a highly affected country 176
Multidisciplinary consensus on the diagnosis and management of patients with atypical Hemolytic Uremic Syndrome (complement-mediated TMA): recommendations from Italian scientific societies, patient associations and regulators 174
The 12-item psoriatic arthritis impact of disease questionnaire : Construct validity, reliability, and interpretability in a clinical setting 172
Sex and Management of Rheumatoid Arthritis 171
Tocilizumab in the treatment of rheumatoid arthritis : An evidence-based review and patient selection 170
Difficult-to-treat psoriatic arthritis: refining the definition using a statistical model in a real-life cohort 168
Tight control in patients with rheumatoid arthritis treated with targeted therapies across the COVID-19 pandemic era 161
Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations : similarities and differences 159
The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials 152
The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors 152
Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors 150
Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? 150
The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept : Retrospective analysis of a local registry 150
The management of first-line biologic therapy failures in rheumatoid arthritis : current practice and future perspectives 148
Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28scores 147
The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study 147
Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis 146
Real-world experience of tocilizumab in rheumatoid arthritis : sub-analysis of data from the Italian biologics’ register GISEA 146
A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: Focus on interchangeability 146
Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis 144
An Italian Disease-Based Registry of Axial and Peripheral Spondyloarthritis : The SIRENA Study 143
Upadacitinib and filgotinib: The role of JAK1 selective inhibition in the treatment of rheumatoid arthritis 141
Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy 140
Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: Long-term real-life data from the Lorhen registry 139
Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis 137
Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules : A multicentre retrospective study 136
Sarilumab : patient-reported outcomes in rheumatoid arthritis 136
Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects 136
Spotlight on mavrilimumab for the treatment of rheumatoid arthritis : Evidence to date 134
Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study) 133
Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine 133
Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis : a structured literature review 132
Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis 132
Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission 132
Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients 130
Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN) = Efficacia e sicurezza degli agenti anti-TNF nel registro Lombardo (LORHEN) 129
Is there really room for anti-rheumatic drugs in the treatment of COVID-19? 129
Immune response to SARS-COV-2 infection in patients with rheumatic musculoskeletal diseases: the mainstream study 127
The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrolment: data from a systematic review and meta-analysis 127
Erratum to: Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis 126
Novel Mechanisms of Action of the Biologicals in Rheumatic Diseases 123
High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: Data from GISEA, the Italian biologics register 122
The profiling of axial spondyloarthritis patient candidate to a biologic therapy : consensus from a Delphi-panel of Italian experts 122
Short-term exposure to outdoor air pollutants and rheumatoid arthritis activity in metropolitan areas in the North of Italy 122
Effect of neridronate on axial involvement in patients with spondyloarthritis when biologics are not possible. Results of a monocentric study 118
Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors : real-life data from the LORHEN registry 118
Il nodulo reumatoide 117
The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry 117
Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs 115
Treatment comparison in rheumatoid arthritis : head-to-head trials and innovative study designs 115
Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection 115
TNF-α antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice 114
Vitamin D and spondyloarthritis: Review of the literature 113
Clinical evaluation of a novel chemiluminescent immunoassay for the detection of anti-citrullinated peptide antibodies 111
Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis 109
Anti-TNFα therapy in a cohort of rheumatoid arthritis patients : clinical outcomes 109
The change over time in the prescription pattern of the first targeted drug after failure of conventional therapy in patients with rheumatoid arthritis: a 20-year real-world experience 107
Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium 106
Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis : real-life data from the Italian LORHEN Registry 105
Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: An observational study in Italy 105
Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights 104
Dr. Favalli, et al. reply 103
Whole-Blood RNA Sequencing Profiling of Patients With Rheumatoid Arthritis Treated With Tofacitinib 101
Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis 101
Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry 101
Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities 100
Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review 98
Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis 98
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab : results from the Italian GISEA registry 97
Axial Spondyloarthritis: Reshape the Future—From the “2022 GISEA International Symposium” 96
Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis 96
Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry 93
The management of acute anterior uveitis complicating spondyloarthritis: Present and future 93
Change over time in the pattern of clinical response to first-line biologic drugs in patients with rheumatoid arthritis: Observational data in a real-life setting 93
Totale 17.633
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.417
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.417
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021180 0 0 0 0 0 0 0 0 0 0 99 81
2021/20221.516 58 55 65 99 100 82 78 277 201 139 115 247
2022/20231.742 217 144 138 151 189 313 93 108 169 38 142 40
2023/20241.359 49 93 79 111 345 105 82 65 50 79 109 192
2024/20254.082 106 433 175 333 328 194 245 366 250 383 430 839
2025/20268.117 739 593 915 780 735 541 1.202 405 766 561 880 0
Totale 20.694